IMPORTANCE Although deep learning (DL) can identify the intermediate or advanced stages of age-related macular degeneration (AMD) as a binary yes or no, stratified gradings using the more granular Age-Related Eye Disease Study (AREDS) 9-step detailed severity scale for AMD provide more precise estimation of 5-year progression to advanced stages. The AREDS 9-step detailed scale's complexity and implementation solely with highly trained fundus photograph graders potentially hampered its clinical use, warranting development and use of an alternate AREDS simple scale, which although valuable, has less predictive ability.
A pproximately 8 million people older than 50 years have intermediate-stage age-related macular degeneration (AMD). 1 These individuals are at high risk of developing advanced AMD, which if left untreated, is a leading cause of blindness in the United States. 1, 2 The intermediate stage is
defined by large drusen or retinal pigment epithelial abnormalities identified on fundus examination and rigorously quantified using fundus photographs to measure drusen size, drusen area, or pigmentary abnormalities. To quantify AMD severity and study disease progression, the Age-Related Eye Disease Study (AREDS) developed 2 classification scales based on these retinal abnormalities. In particular, a basic 4-step classification scale, which was not based on an analysis of outcome data, was used at entry into AREDS and defined as no AMD (AMD-1), early AMD (AMD-2), intermediate AMD (AMD-3), and advanced AMD (AMD-4). 3 A more detailed, 9-step severity scale (eFigures 1-3 in the Supplement), which was based on outcome data, provided predictive variables for 5-year risk of developing choroidal neovascularization (CNV), central geographic atrophy (GA), or both. [4] [5] [6] This detailed grading of fundus images can be time-consuming and likely limited to highly trained fundus photograph graders. Given the complexity of the 9-step scale, in the absence of trained graders (eg, from fundus photograph reading centers), most physicians probably do not use the AREDS detailed AMD severity scale. A simpler scale was judged to be needed and was developed with more practicality but with less predictive accuracy of 5-year risk.
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People older than 50 years are at greater risk for developing AMD. 8 Currently, there are approximately 1.75 million to 3 million people in the United States with the advanced form of AMD and approximately 110 million more in the at-risk population of people older than 50 years. 1,2,9 Worldwide, it was estimated in 2000 that there were more than 600 million people older than 60 years, with that number being projected to increase to 2.4 billion by 2050. 8 Use of the 9-step scale performed only by highly skilled human graders to determine an individual's 5-year risk of developing the advanced form of AMD is time and cost prohibitive. The objective of this study was to develop automated methods that implement the AREDS 4-step AMD eligibility criteria and the 9-step AMD detailed severity scale using modern deep learning (DL) algorithms to automatically evaluate severity of AMD and risk of progression to advanced AMD from fundus photographs. This automated capability could alleviate the issue of identifying, in a timely manner, individuals at various levels of risk of progression in the population. In addition, it could allow for the objective assessment of detailed disease progression in practice or during enrollment and follow-up of clinical trials for AMD.
Deep learning approaches for automated classification from fundus images differ from traditional machine vision, medical image analysis, and automated retinal image analysis methods, which have relied on computing engineered features from the image. 10, 11 Instead, DL involves feature representations of images with multiple levels of abstraction not by relying on human-identified features but directly from data.
12 Advances in DL were made possible through algorithmic optimization and expanded computational power using graphics processing units and have led to the possibility of using DL evaluation of fundus photographs not only for a 2-step system (referable vs not referable) but also for detailed 4-or 9-step systems. 11,13-18 More detailed systems could determine whether the patient was referable or not and provide the health care system more granular classification that allows better predictive accuracy in the absence of highly trained human graders. The output could be used for more precise counseling of the patient and identification of patients at very high risk of progression to advanced AMD. Such patients might warrant more detailed or frequent monitoring (such as with optical coherence tomography [OCT] or OCT angiography) or may be the basis of more efficient clinical trials that could test preventive treatments on very high-risk individuals wherein the sample size could be kept small.
Methods

Data Set
The National Institutes of Health AREDS data set, including data collected from individuals from November 13, 1992, to November 30, 2005, from whom written informed consent was obtained, was derived from a 12-year longitudinal study designed to improve understanding of the frequency and risk factors of AMD progression. More than 130 000 field-2 stereoscopic color fundus photographs were captured during AREDS from 4613 study participants at the baseline and follow-up visits. Images were quantitatively graded by trained and certified graders at a fundus photograph reading center. 3 The grades assigned to each image were used as a criterion standard for the multiclass classification problems studied herein. To avoid using essentially the same image twice, we handled cases with stereo pairs by removing the image with the poorer quality.
Automated Classification
To perform automated classification, we use DL algorithms known as deep convolutional neural networks (DCNNs) and specifically use the ResNet-50 network. 20 The DCNNs use many computational layers that perform convolutions and nonlinear activation operations. This layered approach results in the identification of image features that represent the original image at different levels of abstraction (low-, middle-, and higherlevel semantic features).
AMD Severity Scales 4-Step Scale
The 4-step AREDS scale for eligibility criteria in AREDS is an eye-based scale defined as follows: (1) eyes with no or only small drusen (drusen size, <63 μm) and no pigmentation abnormalities classified as normal were given a score of 1; (2) eyes with multiple small drusen or medium-sized drusen (drusen size, ≥63 and <125 μm) and/or pigmentation abnormalities related to AMD classified as early stage AMD were given a score of 2; (3) eyes with large drusen (drusen size, ≥125 μm) or numerous medium-sized drusen and pigmentation abnormalities classified as intermediate AMD were given a score of 3; (4) eyes with lesions associated with CNV or GA (eg, retinal pigment epithelial detachment, subretinal pigment epithelial hemorrhage) classified as advanced AMD 3,6,21 were given a score of 4 if the fellow eye did not have central GA or CNV AMD. This scale was used to provide baseline severity levels of AMD in participants enrolling in AREDS. More recently, this 4-step scale was proposed for use in the public domain to identify individuals with intermediate-or advanced-stage AMD who might be referred to health care practitioners for monitoring for the development of advanced-stage AMD and for consideration of dietary supplementation, such as that used in AREDS, to reduce the risk of progression to advanced-stage AMD. For patients with no AMD or early-stage AMD, a referral and consideration of such supplementation might not be indicated.
9-Step Scale
The 9-step severity scale (eFigures 1-3 in the Supplement), which is based on outcome data from AREDS, is an eye-based scale that is more detailed and refined than the 4-step scale described above; the scale grades intricate quantitative features of total drusen area and pigmentation abnormalities.
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Specifically, it combines a 6-step drusen area scale with a 5-step pigmentary abnormality scale to create a 9-step scale with detailed predictability of potential development of advanced AMD in an individual. The 5-year risk of developing the advanced stage, defined as CNV, central GA, or both, increases from approximately 0.3% for an eye at step 1 to 53% for an eye at step 9. 5 The eTable in the Supplement provides a detailed description of the quantitative criteria used to define each of the 9 steps and the corresponding 5-year risk factor associated with each step. 5 Notations C-1, C-2, I-2, O-2, and 0.5 disc area seen in the eTable in the Supplement refer to standard circles used by trained fundus photograph graders to quantitatively measure areas of drusen and pigment abnormalities. 3 Several severity steps have multiple criteria that define the given step, any one of which is sufficient for an eye to be diagnosed at that step. For example, an eye can be diagnosed as step 2 in one of 2 ways: (1) total drusen area greater than or equal to C-1 and less than C-2 and no increased pigment or depigmentation GA or (2) total drusen area less than C-1 and increased depigmentation GA in the questionable category (ie, the grader is at least 50%, but not more than 90%, sure that the abnormality exists) but with less than I-2 and increased pigment in the questionable category. In the AREDS reports, an eye that progressed to central GA (ie, beyond step 9) was given a score of 10, an eye that progressed to CNV was scored 11, and an eye with both central GA and CNV was scored 12. Images with a score of 10, 11, or 12 were not included in the analysis of the 9-step severity scale because having any of these stages corresponds trivially to a 5-year risk probability of 1.
DCNN Classification
For each of the classification problems above (4-step and 9-step scales), a separate multiclass classifier based on a DCNN was trained and tested. Additional details are provided in the eMethods in the Supplement.
Estimating 5-Year Risk of Progression to Advanced AMD Three DL-based methods were used and tested to infer the 5-year risk directly from the fundus image as input. These methods included soft prediction, hard prediction, and regressed prediction.
Soft Prediction
Soft prediction first estimated 9-step class probabilities (p i , i = 1…9) for each of the 9 classes using the DCNN-based classification described above and using the output SoftMax values of the DCNN. Then, the risk estimate E sp was computed as the expected value of the class risk under this probability as R sp =E p [R] = Σ i = 1..9 p i .R i , where R i is the risk ascribed to class i (eTable in the Supplement).
Hard Prediction
As in the previous method, in hard prediction, the 9-step class probabilities (p i , i = 1…9) for each of the 9 classes were estimated using the DCNN-based classification described above. The risk R hp was computed as the risk of the class with maximum probability as R sp =R i* , where i* indicates argmax i = 1..9 (p i ).
Regressed Prediction
Unlike the other 2 methods, regressed prediction skipped the step of predicting the 9-step class for the fundus image and, instead, directly performed DL-based regression by mapping the input image to risk R rp using a DCNN in regression mode. The specific features of the DCNN are similar to those used for classification (ResNet) with changes for regression (L2 loss function instead of cross-entropy and use of a single node on the last layer).
Data Partition
The data consisted of AREDS color fundus images that were subdivided using a train, validate, and test split of 88%, 2%, and 10%, respectively. This split is within typical values that are judged to be adequate; 2% left for validation still contains more than 1000 images. Care was taken that all images for a given study participant were comprised wholly within a partition. As described previously, 17 a total of 67 401 images were used for the 4-step classification problems. In the case of the 9-step classification problem, some of the 67 401 images had no value assigned to them for the 9-step scale (ie, missing data). These images were removed, and, as noted above, images with severity scores of 10, 11, or 12 were also removed, resulting in 58 370 images available for the 9-step classification problem.
Human-Machine Comparisons
Because many of the gradings of AREDS photographs were performed in the 1990s, we also compared the DCNN algorithms with 21st century human performance by having an ophthalmologist independently grade a subset of 5000 AREDS images using the criteria defined for the 4-step AMD severity scale. These grades and the machine-generated grades were each compared with the criterion standard AREDS AMD grades from the fundus photograph reading center.
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Metrics
The metrics used to assess the quality of performance were linearly weighted κ (κw) score, accuracy, and confusion matrix. 3, 22, 23 Although accuracy is a commonly used metric, κw was a superior measure in this situation (multiclass classification with ordinal classes) for performance evaluation for 2 reasons: κw discounts for chance agreement and weights error based on proximity of classes, whereas accuracy penalizes equally across classes when, for example, erroneously classifying an AMD-1 as an AMD-2 as opposed to AMD-4. For the confusion matrix ( Figure 1 ), our convention used rows to represent the sample count for the true class, and columns provided the classifier prediction counts. Thus, the sum of each row equals the total number of images in each class, and the diagonal elements give the total number the classifier classified correctly in each class. Off-diagonal elements showed the number of images misclassified and how they were misclassified. Accuracies that represent population-specific class distributions can be computed from the confusion matrix.
Results
This study used 67 401 color fundus images from the 4613 study participants. Figure 1 reports the results of the multiclass classification for the 4-step and 9-step AMD severity scales. Results of the 4-step classification showed machine performance comparable to that of the ophthalmologist: comparing machine vs human, results for the 4-class classification were a κw of 0.773 and an accuracy of 75.7% vs a κw of 0.753 and an accuracy of 73.8%. Both human and machine had the greatest difficulty correctly classifying AMD-2, with human obtaining correct scores on 463 of 1194 images (38.8%) and the machine on 915 of 1711 images (53.5%). Furthermore, both human and machine made the largest percentage error misclassifying AMD-2 as AMD-1, with humans misclassifying 559 of 1194 images (46.8%) and the machines 585 of 1711 images (34.2%), which should have little clinical relevance. The next largest percentage error for each was misclassifying AMD-4 as AMD-3, with human misclassifying 117 of 653 images (17.9%) and the machine misclassifying 171 of 974 images (17.6%). For the 9-step classification, κw was 0.738, suggesting substantial agreement with the criterion standard. From the confusion matrix for the 9-step classification, the machine had the greatest difficulty correctly classifying patients with severity scores of 3, 2, and 6, achieving accuracy of 9.7% (32 of 330 images) for step 3, 20.8% (151 of 725 images) for step 2, and 25.2% (122 of 484 images) for step 6. The largest percentage of misclassification error for the 9-step classification was misclassifying step 2 as step 1 (462 of 725 images [63.7%]). The next 3 largest misclassification errors were These aforementioned misclassifications were all made to adjacent classes with similar 5-year risk factors. Class imbalance and paucity of training exemplars for some classes appear to partly explain where the machine performance decreased. For example, in the 9-step classification, the 4 least represented classes were class 9 (90 images), class 8 (296 images), class 3 (330 images), and class 7 (391 images).
On the other hand, the large fraction of class 2 cases that were misclassified as class 1 may be indicative of the intrinsic difficulty in distinguishing class 2 from class 1 as well as the imbalance between the 2 classes (>3 to 1). The Table summarizes performance for 5-year risk probability prediction for each of the 3 methods: soft, hard, and regressed prediction. Error distribution is shown for all 3 methods in Figure 2 in which box plots are plotted against each step going from 1 through 9. The x-axis indicates the values of the 5-year risk for each step (rather than the step value itself) as reported previously 5 and ranges from 0.3% and 0.6% for steps 1 and 2 to 47.4% and 53.2% for steps 8 and 9. From the top downward, errors are shown for soft, hard, and regressed 5-year risk estimates. The left plots show unsigned errors and the right plots show signed errors. Trends show interquartile values of errors increasing consistently with higher AMD steps values. Likewise, median values of unsigned error increase consistently with higher step value. The overall mean estimation error for the 5-year risk ranged from 3.47% to 5.29% (Table) . The error on 5-year estimated risk was smaller for lower-risk classes. Of the 3 methods, the hard prediction performed best for all classes except for class 3, in which the soft prediction outperformed all (mean [SD] prediction error, 1.92% [2.91%]; median, 1.28%), and class 6, in which the regressed prediction outperformed all (mean [SD] prediction error, 7.67% [5.37%]; median, 6.69%). For class 7, the soft prediction had the smallest mean (5.45%), whereas the hard prediction had the smallest median (0%).
Discussion
For the 4-step classification used for eligibility criteria in AREDS, this study matched human performance as seen previously in a 2-step classification. 17 For the classification based on a 4-step severity scale, the machine performed on par with a 21st-century ophthalmologist grading, and based on κw, and both showed substantial agreement with the AREDS criterion standard grading. 3,23 Both human and machine had the greatest difficulty correctly classifying AMD-2. Specifically, both human and machine made the largest percentage error misclassifying AMD-2 as AMD-1, which should have little clinical relevance. The next largest percentage error for each was misclassifying AMD-4 as AMD-3. All misclassifications assume that the human fundus photograph grading, as the criterion standard, was always correct. The classification based on the 9-step severity scale based on outcome data was conducted by the machine compared with prior gradings by AREDS fundus photograph graders. Because of the increased number of classes, the total accuracy for the 9-step classification, as expected, was inferior to the 4-step classification. Nevertheless, the κw in this investigation, which took into account errors made to adjacent classes and assessed agreement beyond chance alone, indicated substantial agreement between the machine and the AREDS criterion standard by trained human graders. 3, 22, 23 In contrast to
another recently published investigation 18 of DCCNs applied to a 12 plus 1-step AREDS detailed scale (in which the additional classes correspond to steps 10, 11, and 12, as well as a class for ungraded images), our study focused on the novel task of estimating the 5-year risk probability using automated identification of a fundus image as 1 of 9 increasingly at-risk steps in AMD progression. Both studies, however, revealed corresponding levels of classification performance, considering margins of error, with differences likely attributable to differing number of classes (steps 10-12 and ungraded images are not relevant to estimating risk for advanced AMD), data use, and Reading from the confusion matrix for the 9-step classification, the machine had the greatest difficulty correctly classifying patients with severity scores of 3, 2, and 6. The largest percentage of misclassification error for the 9-step classification was misclassifying step 2 as step 1. The next 3 largest misclassification errors consisted of step 8 misclassified as step 7, step 9 misclas- 
Regressed predictions
The boxes extend from the lower to upper quartile values of the data, with a line at the median. The whiskers extend from the box to show the range of the data. Flier (outlier) points are those past the end of the whiskers.
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Deep Learning for Severity Characterization and Risk Estimation in Age-Related Macular Degeneration sified as step 8, and step 3 misclassified as step 1. These abovementioned misclassifications were all made to adjacent classes with similar 5-year risk factors. Class imbalance and paucity of training exemplars for some classes likely explain where the machine performance decreased: in the 9-step classification, the 4 least represented classes were class 9 (90 images), class 8 (296 images), class 3 (330 images), and class 7 (391 images). On the other hand, the large fraction of class 2 cases that were misclassified as class 1 may be suggestive of the intrinsic difficulty in distinguishing class 2 from class 1 as well as the imbalance between the 2 classes (>3 to 1). These factors should motivate the future use of DL techniques that work with only a few training examples.
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In aggregate, preliminary findings suggest that DL methods may help in fine delineation of fundus and OCT, which also may help refine retinal diagnostics. 25 Furthermore, similar to the 4-step scale, these findings suggest that the 9-step scale from DL may be used in the public domain to screen individuals with referable AMD with greater granularity of predictability for progression to advanced AMD as well as for use by ophthalmologists assessing risk of AMD in an individual beyond that provided by the simple scale. 7 In addition, the greater predictive capability of the 9-step scale may make it more appealing for use in clinical trials to assess efficacy of new therapies that have small sample sizes, especially when the rate of progression to advanced AMD is higher than that determined by 4-step or simple scale eligibility criteria, while avoiding the complexity of training individuals to provide reliable and reproducible gradings.
Limitations
A possible limitation of this study is that the AREDS fundus photographs are primarily composed of images from white participants. In addition, as previously noted for the 9-step classification problem, there are large class imbalances among some of the classes. For example, for the 9-step scale, there were 24 411 images classified as step 1 and only 1160 images classified as step 9. To a lesser extent, this issues also exist for the 4-step scale in which there were a total of 20 801 images classified as AMD-1 and only 9023 AMD-4 images.
Conclusions
In summary, DL achieved results comparable to those of a physician and κw showing substantial agreement with the criterion standard on a large, complex, severity-scale data set, performing well in all categories except those with few training samples. Preliminary results show promise for future use of DL to assist physicians in longitudinal care for individualized, detailed risk assessment as well as clinical studies of disease progression during treatment. Deep learning may also eventually be used for public screening or monitoring in developed and developing countries worldwide that could assist in referring individuals to a health care practitioner when indicated and feasible. form of artificial intelligence called deep learning to fundus images from the Age-Related Eye Disease Study (AREDS) to estimate 5-year risk of developing advanced age-related macular degeneration (AMD). The machine's performance was then compared with that of a present-day ophthalmologist, with comparable results; the human grader was 73.8% accurate at classifying images using the original AREDS 4-step AMD classification, and the machine was 75.7% accurate. When the machine was tasked with classifying images by the significantly more complex AREDS 9-step severity scale, accuracy was reduced to 59.1%. When tasked with calculating the 5-year risk of advanced AMD without the intermediate step of estimating an image's 9-step severity class and consequent risk, it performed worse than 2 algorithms for all but 1 class that estimated the 9-step class as a first step.
Deep learning is a highly sophisticated form of machine learning in which a computer program evolves to generate an output, for instance, classifying a fundus photograph as demonstrating diabetic retinopathy or not through exposure to labeled data and with little to no explicit programming from human programmers about the specific task. A program with no specific programmer input is called unsupervised learning, and those with greater levels are referred to as supervised learning. An essential input to train these programs is an abundance of labeled data, such as fundus photographs demonstrating different disease states or severity levels that have already been accurately labeled by an expert in diagnosis and classification. Deep learning represents a veritable quantum leap in artificial intelligence, made possible in large part by the creation and refinement of artificial neural network architectures and training strategies, such as the one used by Burlina et al. 1 Artificial neural networks are a complex form of artificial intelligence that feature data inputs into artificial neurons, or nodes, that interpret and transform specific features of the data that they have been fed and then feed that data into other nodes in the network that perform their own transformation and so on. Neurons in these networks can also feed back onto prior ones. In essence, their objective is to mimic the structure and processing power of the human neural network, which is composed of billions of interconnected neurons that process complex inputs, such as sensory information from the outside world, or perform higher cortical functions, such as executive decision-making. Medical imaging is a natural application of deep learning because the images are com-
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eMethods. Additional Points of Clarification
Additional points of clarification not contained in the manuscript are included below:
Details on Network Architecture and Training Methodology
For deep learning, we use the Keras framework (https://keras.io) and make use of its native ResNet50 model. We additionally utilize the native weights of the network, which were pre-trained on the ImageNet dataset, and we then fine-tune these weights with retinal images for the tasks that are reported in the paper, a process referred to as transfer learning. While ImageNet images differ substantially from retinal fundus images, the use of pre-trained weights still helps, most likely in early layers of the network, which focus on basic edge detection like filters, rather than understanding the semantics of the image. We replace the last softmax layer of the network with one that does softmax but contains a number of outputs equal to the number of classes in our experiments (or, alternatively, only a single-node linear activation layer for the regression methods).
For model training, we use a stochastic gradient descent (SGD) optimizer, with Nesterov momentum of 0.9, to minimize a categorical cross entropy loss function (or a mean squared error loss function for the regression case). During training, we utilize a dynamic learning rate schedule, which multiplies the learning rate by 0.5 when the training loss doesn't improve for 10 epochs. Additionally, if the validation loss does not improve for 20 epochs, training is stopped, and the model snapshot (saved on every epoch) with the best validation loss (the dataset was previously subdivided into train/validation/test) is saved as the final model weights. Through hyperparameter optimization on our validation set, we settled on a base learning rate of 0.001 and a batch size of 32.
We additionally employ data augmentation on each batch fed into the network during training. Images are augmented with horizontal flipping, small amounts of blurring or sharpening, as well as various adjustments to saturation, brightness, contrast, and color balance.
Details on Retinal Pre-processing
We used a method that is similar to that reported in 17 . in which we used a preprocessing of the input fundus image by detecting the outer boundaries of the retina, cropping images to the square that is inscribed within the retinal boundary, and resizing the square to fit the expected input size of the network. Here the expected input size for the ResNet network is 224 x 224 pixels 20 .
Classification with Additional Classes
The advanced form of AMD is considered level 10 or higher. The main focus of this study is on classes 1-9 because our stated end goal is to predict the probability for the eye to advance to levels 10-11-12. If an eye is already a 10-11-12, then the probability that it advances to the severe stages of 10-11-12 is trivially equal to 1. In the interest of completeness, we succinctly note that the methods herein can also apply to the 12-class problem, and yield (improved) metrics as follows: accuracy (CI error margin): 60.12% (1.17) and linear weighted kappa = 0.8057. By comparison to another recently published investigation 18 (not available at the time of this submission) of DCCNs applied to a 12+1-step AREDS detailed scale (where the additional classes correspond to steps 10,11 and 12, as well as a class for ungraded images), our study focusses on the novel task of predicting the 5-year risk probability via the 9-step scale. Both studies however point to somewhat related levels of classification performance considering various factors mentioned in the discussion section.
Potential Deployment Scenarios
Regarding real world clinical deployment and what classification should be used, several possibilities can be envisaged, including for example: having a single 12 class classifier as noted earlier; having a 13 class classifier with a 'bad quality' class; having a cascaded decision process with several classifiers: one that checks quality and recommends that the fundus imager retake an image in case quality is insufficient, followed by a second stage classifier that predicts the current state of the eye based on a 4 class classification (as we report in this paper) that would help refer individuals to be seen or not by a specialist, this would then be followed by another stage predictor that would work in the clinic and predict the probability of advancing if the eye is not already in the advanced stage (via the 9 class predictor we address in this study).The first and second stages could work automatically in a kiosk, teleophthalmology, point of care, or self scanning scenario, and the third stage would work in the clinic, and help a clinician decide on a course of action. In the end, how one would actually structure classification for deployment really would depend on the actual clinical workflow. Our inclination is that a three stage system, with a human clinician in the loop and a machine assisting him/her is probably a potentially viable approach for deployment. But many other choices are possible.
Saliency Maps
The problem of interpretably of DCNNs and addressing their inherent black box-ness is important to ensure trust in their workings and allow their future use in clinical applications. Research on tools that allow for greater interpretation of DCNNs workings is still ongoing. However, saliency maps can offer a simple way to visualize what the network activates on. As the example shown in the eFigure 1 suggests, the saliency map points to the network likely activating on lesions and specific drusen, which seems therefore to indicate that the network is probably looking at the "right'' locations when making a decision.
Visits during AREDS
For each visit, a stereoscopic pair of images was taken for each eye and, for each stereoscopic pair, we only used one of the stereo images per eye. Also note: In some visits only one eye was imaged in the AREDS study. There are a variable number of visits for each subject, some individuals attended for the full 12 years, while some were much shorter lived.
AREDS Analog Image Conversion
Note that the AREDS images used here were originally taken from analog images that were subsequently digitally scanned. Performance on digital images may therefore vary and may entail improvement or worsening, but likely would lead to improved performance. More discussions on this topic can be found in: Automated Classification 
Model weights
Model weights may be shared with interested parties if used solely for research and noncommercial and non-clinical/diagnostic purposes and provided that appropriate usage and legal safeguards are employed. Request should be made by contacting the corresponding author.
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